Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 5.1%

GT Biopharma, Inc. (NASDAQ:GTBP) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 196,500 shares, a growth of 5.1% from the January 15th total of 186,900 shares. Based on an average daily volume of 431,600 shares, the days-to-cover ratio is currently 0.5 days. Currently, 10.0% of the company’s shares are sold short.

Analyst Ratings Changes

Several research analysts have commented on the company. Roth Capital upgraded GT Biopharma to a “strong-buy” rating in a report on Monday, December 2nd. Roth Mkm initiated coverage on shares of GT Biopharma in a report on Monday, December 2nd. They issued a “buy” rating and a $11.00 target price for the company.

GT Biopharma Trading Down 1.9 %

Shares of GT Biopharma stock opened at $2.10 on Wednesday. The company has a 50-day simple moving average of $2.49 and a two-hundred day simple moving average of $2.48. GT Biopharma has a one year low of $1.72 and a one year high of $10.66.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.